Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8536294 | 0.97 | TPMT (0.36) | TPMTCYP1A2LMNACA12CA1 | |
| SCHEMBL1859003 | 0.97 | TPMT (0.39) | TPMTCYP1A2LMNACA12CA1 | |
| Hydrochloric Acid SCHEMBL8824728 | 0.93 | TPMT (0.38) | TPMTCYP1A2LMNACA12CA1 | |
| SCHEMBL7596897 | 0.93 | TPMT (0.41) | TPMTCYP1A2LMNACA12CA1 | |
| SCHEMBL4587818 | 0.93 | TPMT (0.41) | TPMTCYP1A2LMNACA12CA1 | |
| SCHEMBL9600105 | 0.90 | TPMT (0.39) | TPMTCYP1A2LMNACA12CA1 | |
| SCHEMBL4265757 | 0.90 | TPMT (0.39) | TPMTCYP1A2LMNACA12CA1 | |
| Hydrochloric Acid SCHEMBL9787611 | 0.90 | TPMT (0.39) | TPMTCYP1A2LMNACA12CA1 | |
| Hydrochloric Acid SCHEMBL8541347 | 0.90 | TPMT (0.39) | TPMTCYP1A2LMNACA12CA1 | |
| SCHEMBL8855992 | 0.90 | TPMT (0.39) | TPMTCYP1A2LMNACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228774-A1 | SYSTEMS AND METHODS FOR ACCELERATED HYDROLYSIS OF POLYSACCHARIDE-BASED HYDROGELS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2025100238-A1 | EPOXY COMPOUND AND USE THEREOF | 四国化成工業株式会社 | 2025-05-15 | — | — | WO | disclosed |
| US-20250136760-A1 | AMINO-ACID- AND AMINO-ALCOHOL-BASED POLYAMINE COMPOUNDS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-5851511-A | Polyiodo compounds, their preparation and their use in X-ray radiology | GUERBET S.A. (FR) | 1998-12-22 | — | — | US | disclosed |
| US-5693311-A | Polyiodinated compounds, process for preparing them and diagnostic compositions | GUERBET S.A. (FR) | 1997-12-02 | — | — | US | disclosed |
| US-4053510-A | REACTING A DICARBOXYLIC ACID WITH UREA IN CHLOROSULFONIC ACID OR OLEUM | AKZO N.V. (NL) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228774-A1 | SYSTEMS AND METHODS FOR ACCELERATED HYDROLYSIS OF POLYSACCHARIDE-BASED HYDROGELS | MGAM, SI, AGL | TPMT 4651/4885CYP1A2 2436/4885LMNA 2099/4885 |
| US-20250136760-A1 | AMINO-ACID- AND AMINO-ALCOHOL-BASED POLYAMINE COMPOUNDS AND MEDICAL HYDROGELS FORMED THEREFROM | CARM1, PNMT, ADM2 | TPMT 3851/4885CYP1A2 2052/4885LMNA 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.